Xilio Therapeutics, Inc. (XLO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
11/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseXLO / S&P 13.91% / 15.20% |
WinXLO / S&P 327.25% / 15.00% |
LoseXLO / S&P -75.28% / 50.40% |
| 2026-Q11/3 |
LoseXLO / S&P -6.14% / -4.33% |
WinXLO / S&P 476.71% / 11.30% |
LoseXLO / S&P -60.94% / 27.70% |
| 2025-Q40/3 |
LoseXLO / S&P -24.08% / 2.65% |
LoseXLO / S&P XLO unavailable / 9.00% |
LoseXLO / S&P -43.80% / 13.40% |
| 2025-Q32/3 |
WinXLO / S&P 23.97% / 8.12% |
LoseXLO / S&P XLO unavailable / 4.61% |
WinXLO / S&P 1018.02% / 13.45% |
| 2025-Q21/3 |
LoseXLO / S&P -6.08% / 10.94% |
LoseXLO / S&P XLO unavailable / 4.83% |
WinXLO / S&P 816.59% / 10.63% |
| 2025-Q11/3 |
LoseXLO / S&P -24.19% / -4.27% |
LoseXLO / S&P XLO unavailable / 4.98% |
WinXLO / S&P 572.37% / 10.57% |
| 2024-Q42/3 |
WinXLO / S&P 21.19% / 2.41% |
LoseXLO / S&P XLO unavailable / 5.25% |
WinXLO / S&P 454.32% / 6.15% |
| 2024-Q30/3 |
LoseXLO / S&P -16.88% / 5.89% |
LoseXLO / S&P XLO unavailable / 5.89% |
LoseXLO / S&P -41.89% / 6.11% |
| 2024-Q20/3 |
LoseXLO / S&P -12.22% / 4.28% |
LoseXLO / S&P XLO unavailable / 5.38% |
LoseXLO / S&P -31.27% / 5.12% |
| 2024-Q11/3 |
WinXLO / S&P 96.36% / 10.56% |
LoseXLO / S&P XLO unavailable / 5.71% |
LoseXLO / S&P -21.41% / 5.59% |
| 2023-Q40/3 |
LoseXLO / S&P -73.93% / 11.69% |
LoseXLO / S&P XLO unavailable / 6.81% |
LoseXLO / S&P -13.66% / 7.78% |
| 2023-Q30/3 |
LoseXLO / S&P -19.47% / -3.27% |
LoseXLO / S&P XLO unavailable / 7.52% |
LoseXLO / S&P -104.91% / -5.03% |
| 2023-Q20/3 |
LoseXLO / S&P -17.35% / 8.74% |
LoseXLO / S&P XLO unavailable / 9.50% |
LoseXLO / S&P -107.73% / -8.57% |
| 2023-Q11/3 |
WinXLO / S&P 17.84% / 7.50% |
LoseXLO / S&P XLO unavailable / 10.77% |
LoseXLO / S&P -135.82% / -15.69% |
| 2022-Q40/3 |
LoseXLO / S&P -7.56% / 7.56% |
LoseXLO / S&P XLO unavailable / 11.88% |
LoseXLO / S&P -76.36% / -17.99% |
| 2022-Q31/3 |
WinXLO / S&P -0.34% / -4.88% |
LoseXLO / S&P XLO unavailable / 13.47% |
LoseXLO / S&P -154.94% / -1.41% |
| 2022-Q20/3 |
LoseXLO / S&P -58.70% / -16.10% |
LoseXLO / S&P XLO unavailable / 13.71% |
LoseXLO / S&P -135.27% / 11.04% |
| 2022-Q10/3 |
LoseXLO / S&P -55.81% / -4.60% |
LoseXLO / S&P XLO unavailable / 15.97% |
LoseXLO / S&P XLO unavailable / 42.23% |
| 2021-Q40/3 |
LoseXLO / S&P XLO unavailable / 11.03% |
LoseXLO / S&P XLO unavailable / 15.00% |
LoseXLO / S&P XLO unavailable / 96.40% |
| 2021-Q30/3 |
LoseXLO / S&P XLO unavailable / 0.58% |
LoseXLO / S&P XLO unavailable / 10.77% |
LoseXLO / S&P XLO unavailable / 69.42% |
| 2021-Q20/3 |
LoseXLO / S&P XLO unavailable / 8.55% |
LoseXLO / S&P XLO unavailable / 6.58% |
LoseXLO / S&P XLO unavailable / 51.81% |
| 2021-Q10/3 |
LoseXLO / S&P XLO unavailable / 6.17% |
LoseXLO / S&P XLO unavailable / -1.06% |
LoseXLO / S&P XLO unavailable / 7.39% |
| 2020-Q40/3 |
LoseXLO / S&P XLO unavailable / 12.15% |
LoseXLO / S&P XLO unavailable / -3.72% |
LoseXLO / S&P XLO unavailable / -33.42% |
| 2020-Q30/3 |
LoseXLO / S&P XLO unavailable / 8.93% |
LoseXLO / S&P XLO unavailable / -2.04% |
LoseXLO / S&P XLO unavailable / -27.10% |
| 2020-Q20/3 |
LoseXLO / S&P XLO unavailable / 20.54% |
LoseXLO / S&P XLO unavailable / -0.46% |
LoseXLO / S&P XLO unavailable / -27.11% |
| 2020-Q10/3 |
LoseXLO / S&P XLO unavailable / -19.60% |
LoseXLO / S&P XLO unavailable / 3.47% |
LoseXLO / S&P XLO unavailable / -14.75% |
| 2019-Q40/3 |
LoseXLO / S&P XLO unavailable / 9.07% |
LoseXLO / S&P XLO unavailable / 5.36% |
LoseXLO / S&P XLO unavailable / 2.99% |
| 2019-Q30/3 |
LoseXLO / S&P XLO unavailable / 1.70% |
LoseXLO / S&P XLO unavailable / 5.02% |
LoseXLO / S&P XLO unavailable / 0.21% |
| 2019-Q20/3 |
LoseXLO / S&P XLO unavailable / 4.30% |
LoseXLO / S&P XLO unavailable / 6.64% |
LoseXLO / S&P XLO unavailable / 8.65% |
| 2019-Q10/3 |
LoseXLO / S&P XLO unavailable / 13.65% |
LoseXLO / S&P XLO unavailable / 8.12% |
LoseXLO / S&P XLO unavailable / 14.29% |
| 2018-Q40/3 |
LoseXLO / S&P XLO unavailable / -13.52% |
LoseXLO / S&P XLO unavailable / 9.05% |
LoseXLO / S&P XLO unavailable / 18.23% |
| 2018-Q30/3 |
LoseXLO / S&P XLO unavailable / 7.71% |
LoseXLO / S&P XLO unavailable / 10.21% |
LoseXLO / S&P XLO unavailable / 19.06% |
| 2018-Q20/3 |
LoseXLO / S&P XLO unavailable / 3.43% |
LoseXLO / S&P XLO unavailable / 9.03% |
LoseXLO / S&P XLO unavailable / 14.46% |
| 2018-Q10/3 |
LoseXLO / S&P XLO unavailable / -0.76% |
LoseXLO / S&P XLO unavailable / 7.68% |
LoseXLO / S&P XLO unavailable / 12.46% |
| 2017-Q40/3 |
LoseXLO / S&P XLO unavailable / 6.64% |
LoseXLO / S&P XLO unavailable / 7.03% |
LoseXLO / S&P XLO unavailable / 13.82% |
| 2017-Q30/3 |
LoseXLO / S&P XLO unavailable / 4.48% |
LoseXLO / S&P XLO unavailable / 5.68% |
LoseXLO / S&P XLO unavailable / 17.57% |
| 2017-Q20/3 |
LoseXLO / S&P XLO unavailable / 3.09% |
LoseXLO / S&P XLO unavailable / 4.83% |
LoseXLO / S&P XLO unavailable / 17.74% |
| 2017-Q10/3 |
LoseXLO / S&P XLO unavailable / 6.07% |
LoseXLO / S&P XLO unavailable / 3.67% |
LoseXLO / S&P XLO unavailable / 13.32% |
| 2016-Q40/3 |
LoseXLO / S&P XLO unavailable / 3.82% |
LoseXLO / S&P XLO unavailable / 2.09% |
LoseXLO / S&P XLO unavailable / 7.05% |
| 2016-Q30/3 |
LoseXLO / S&P XLO unavailable / 3.85% |
LoseXLO / S&P XLO unavailable / 0.20% |
LoseXLO / S&P XLO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | XLO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -8.06% | 20.78% |
| Annualized return | -8.06% | 20.78% |
5Y · 2021-10-22 to 2026-08-27
| Metric | XLO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.98% | 83.14% |
| Annualized return | -47.41% | 12.86% |
10Y · 2021-10-22 to 2026-08-27
| Metric | XLO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.98% | 319.30% |
| Annualized return | -27.48% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |